Budipine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Budipine is an antiparkinson agent.

Its mechanism of action is not well characterized.^[2] It is believed to be an NMDA receptor antagonist,^[3] however, promoting the synthesis of dopamine.^[4]

Because it provides additional benefits relative to existing treatments, it probably does not precisely mimic the mechanism of an existing known treatment.^[5]

References

↑ Martndale: The Complete Drug Reference, 35th Ed.
↑ Reichmann H (October 2006). “Budipine in Parkinson’s tremor”. J. Neurol. Sci. 248 (1–2): 53–5. doi:10.1016/j.jns.2006.05.039. PMID 16784759.
↑ J. Kornhuber, B. Herr, J. Thome, P. Riederer. “The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue”. J.Neural Transm.Suppl. 46:127-133, 1995. PMID 8821048
↑ “umm.edu”.
↑ Przuntek H, Bittkau S, Bliesath H; et al. (May 2002). “Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen”. Arch. Neurol. 59 (5): 803–6. doi:10.1001/archneur.59.5.803. PMID 12020263.

[1] Martndale: The Complete Drug Reference, 35th Ed.

[pmid16784759-2] Reichmann H (October 2006). “Budipine in Parkinson’s tremor”. J. Neurol. Sci. 248 (1–2): 53–5. doi:10.1016/j.jns.2006.05.039. PMID 16784759.

[3] J. Kornhuber, B. Herr, J. Thome, P. Riederer. “The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue”. J.Neural Transm.Suppl. 46:127-133, 1995. PMID 8821048

[url-4] “umm.edu”.

[pmid12020263-5] Przuntek H, Bittkau S, Bliesath H; et al. (May 2002). “Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen”. Arch. Neurol. 59 (5): 803–6. doi:10.1001/archneur.59.5.803. PMID 12020263.

[2]

[3]

[4]

[5]

Budipine

Overview

See also

References